178445-86-8 Usage
Description
1,1-DIMETHYLETHYL [3-[3-(3,4-DIMETHOXYPHENYL)-1-OXO-PROPYL]PHENOXY]-ACETATE is a complex organic compound characterized by the presence of a phenoxy group and an acetate group. It is derived from the combination of 3-(3-(3,4-dimethoxyphenyl)-1-oxo-propyl)phenoxy and 1,1-dimethylethyl, indicating a molecular structure that may offer a range of potential applications. Its intricate design suggests it could be utilized in various scientific fields, including pharmaceuticals, agrochemicals, and materials science, although further research is needed to ascertain its specific uses and properties. Given its complexity, this chemical would require careful handling and evaluation of its impact on human health and the environment.
Uses
Used in Pharmaceutical Industry:
1,1-DIMETHYLETHYL [3-[3-(3,4-DIMETHOXYPHENYL)-1-OXO-PROPYL]PHENOXY]-ACETATE is used as a potential active pharmaceutical ingredient for its possible therapeutic properties, which may be harnessed in the development of new drugs. Its unique structure could provide novel mechanisms of action or improved pharmacokinetics.
Used in Agrochemical Industry:
In the agrochemical sector, 1,1-DIMETHYLETHYL [3-[3-(3,4-DIMETHOXYPHENYL)-1-OXO-PROPYL]PHENOXY]-ACETATE may serve as a component in the formulation of pesticides or herbicides, leveraging its chemical properties to target specific pests or weeds effectively while minimizing environmental impact.
Used in Materials Science:
1,1-DIMETHYLETHYL [3-[3-(3,4-DIMETHOXYPHENYL)-1-OXO-PROPYL]PHENOXY]-ACETATE could be utilized in materials science for the development of new polymers or composites with enhanced properties, such as improved strength, flexibility, or resistance to environmental factors.
Check Digit Verification of cas no
The CAS Registry Mumber 178445-86-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,8,4,4 and 5 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 178445-86:
(8*1)+(7*7)+(6*8)+(5*4)+(4*4)+(3*5)+(2*8)+(1*6)=178
178 % 10 = 8
So 178445-86-8 is a valid CAS Registry Number.
InChI:InChI=1/C23H28O6/c1-23(2,3)29-22(25)15-28-18-8-6-7-17(14-18)19(24)11-9-16-10-12-20(26-4)21(13-16)27-5/h6-8,10,12-14H,9,11,15H2,1-5H3
178445-86-8Relevant articles and documents
RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF
-
Paragraph 0440; 0444, (2021/04/02)
The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have grea
Design and Combinatorial Development of Shield-1 Peptide Mimetics Binding to Destabilized FKBP12
Bols, Mikael,Diness, Frederik,J?rgensen, Frederik P.,Madsen, Daniel,Meldal, Morten,Olsen, Jakob V.,Palmer, Daniel,Roux, Milena E.,Schoffelen, Sanne
, (2020/03/10)
On the basis of computational design, a focused one-bead one-compound library has been prepared on microparticle-encoded PEGA1900 beads consisting of small tripeptides with a triazole-capped N-terminal. The library was screened towards a double
Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35
Atack, Thomas C.,Raymond, Donald D.,Blomquist, Christa A.,Pasaje, Charisse Flerida,McCarren, Patrick R.,Moroco, Jamie,Befekadu, Henock B.,Robinson, Foxy P.,Pal, Debjani,Esherick, Lisl Y.,Ianari, Alessandra,Niles, Jacquin C.,Sellers, William R.
, p. 2131 - 2138 (2020/12/17)
FK506-binding protein 35, FKBP35, has been implicated as an essential malarial enzyme. Rapamycin and FK506 exhibit antiplasmodium activity in cultured parasites. However, due to the highly conserved nature of the binding pockets of FKBPs and the immunosuppressive properties of these drugs, there is a need for compounds that selectively inhibit FKBP35 and lack the undesired side effects. In contrast to human FKBPs, FKBP35 contains a cysteine, C106, adjacent to the rapamycin binding pocket, providing an opportunity to develop targeted covalent inhibitors of Plasmodium FKBP35. Here, we synthesize inhibitors of FKBP35, show that they directly bind FKBP35 in a model cellular setting, selectively covalently modify C106, and exhibit antiplasmodium activity in blood-stage cultured parasites.